MagnetisMM-3
Showing 1 - 25 of >10,000
Relapsed or Refractory Multiple Myeloma Trial in Nagoya, Shibuya-ku (Elranatamab (PF-06863135))
Active, not recruiting
- Relapsed or Refractory Multiple Myeloma
- Elranatamab (PF-06863135)
-
Nagoya, Aichi, Japan
- +1 more
Jun 20, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))
Active, not recruiting
- Multiple Myeloma
- Elranatamab (PF-06863135)
-
Beverly Hills, California
- +75 more
Oct 4, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Lenalidomide)
Recruiting
- Multiple Myeloma
- Elranatamab
- +3 more
-
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
- +7 more
Jan 9, 2023
Medicine Called Elranatamab in People With Relapsed Refractory
Not yet recruiting
- Multiple Myeloma
- Elranatamab
- Standard of care
- (no location specified)
Jun 30, 2023
Multiple Myeloma Trial in Canada, United States (PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 +
Active, not recruiting
- Multiple Myeloma
- PF-06863135 monotherapy IV or SC
- +3 more
-
Encinitas, California
- +37 more
Jul 7, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Pomalidomide)
Recruiting
- Multiple Myeloma
- Elranatamab
- +3 more
-
Woolloongabba, Queensland, Australia
- +117 more
Aug 3, 2022
Multiple Myeloma Trial in Montréal (Elranatamab)
Not yet recruiting
- Multiple Myeloma
-
Montréal, Quebec, CanadaMcGill University Health Centre
Sep 21, 2023
Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)
Recruiting
- Multiple Myeloma
-
Beverly Hills, CaliforniaBeverly Hills Cancer Center
Dec 21, 2022
Multiple Myeloma Trial (Elranatamab (PF-06863135))
Temporarily not available
- Multiple Myeloma
- Elranatamab (PF-06863135)
- (no location specified)
Jul 15, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab, Lenalidomide)
Recruiting
- Multiple Myeloma
-
Benowa, Queensland, Australia
- +132 more
Jan 24, 2023
Post COVID-19 Condition (PCC) Trial in E. Amherst, Milan (RDX-19)
Recruiting
- Post COVID-19 Condition (PCC)
- RDX-19
-
E. Amherst, New York
- +1 more
Oct 30, 2023
Olfactory Cleft Stenosis and Obstruction on Paranasal Sinus CT
Recruiting
- Olfactory Impairment
-
Nancy, France
- +1 more
Oct 8, 2023
Colorectal Cancer Metastatic Trial (Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy
Not yet recruiting
- Colorectal Cancer Metastatic
- Tunlametinib plus Vemurafenib
- Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
- (no location specified)
Aug 15, 2023
Skeletal Muscle Fatty Acid Metabolism Trial in Kingston (Fish oil)
Not yet recruiting
- Skeletal Muscle Fatty Acid Metabolism
- Fish oil
-
Kingston, Ontario, CanadaSchool of Kinesiology and Health Studies
Aug 1, 2023
Alcohol Use Disorder, Severe Trial (Active Comparator: Omega-3, Placebo Comparator: olive oil)
Not yet recruiting
- Alcohol Use Disorder, Severe
- Active Comparator: Omega-3
- Placebo Comparator: olive oil
- (no location specified)
Jun 1, 2023
Solid Tumor, Adult Trial in Tomsk (Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1)
Enrolling by invitation
- Solid Tumor, Adult
- Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1
-
Tomsk, Russian FederationTomskNRMC
Jan 23, 2023
Concussion, Mild Trial in Winnipeg (Omega-3, Placebo)
Not yet recruiting
- Concussion, Mild
- Omega-3
- Placebo
-
Winnipeg, Manitoba, CanadaApplied Research Centre, Faculty of Kinesiology, University of M
Apr 27, 2023
Tomey OA-2000, Tomey CASIA2, and the LenStar LS900
Recruiting
- Cataract
- +2 more
- Optical measurement
-
Woburn, MassachusettsNorthEast Eye Research Associates
Sep 26, 2023
Ovarian Tumors, Endometrial Tumors, Uterine Cervical Tumors Trial (Dostarlimab, Bevacizumab, Doxorubicin)
Not yet recruiting
- Ovarian Neoplasms
- +5 more
- Dostarlimab
- +4 more
- (no location specified)
Sep 3, 2023
Corneal Epithelial Degeneration Trial in Cypress (TTHX1114(NM141) Ophthalmic Solution)
Recruiting
- Corneal Epithelial Degeneration
- TTHX1114(NM141) Ophthalmic Solution
-
Cypress, CaliforniaTrefoil Clinical Site #132
Mar 3, 2023